In silico quantitative structure-activity relationship studies on P-gp modulators of tetrahydroisoquinoline-ethyl-phenylamine series

BMC Structural Biology

Volumn 11, Issue , 2011, Pages

  Gadhe, Changdev G ^a   Madhavan, Thirumurthy ^a   Kothandan, Gugan ^a   Cho, Seung Joo ^a  

^a Chosun University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE; TETRAHYDROISOQUINOLINE ETHYL PHENYLAMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; TETRAHYDROISOQUINOLINE DERIVATIVE;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER MODEL; DRUG STRUCTURE; HUMAN; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG RESISTANCE; MULTIDRUG RESISTANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, MOLECULAR; P-GLYCOPROTEIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES;

EID: 78951492928     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-11-5     Document Type: Article

References (26)

1. Multidrug resistance in cancer: role of ATP-dependent transporters. MM Gottesman T Fojo SE Bates, Nat (Pubitemid 37328807)
2. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. B Sarkadi L Homolya G Szakacs A Varadi, Physiol Rev 2006 86 4 1179 1236 10.1152/physrev.00037.2005 17015488 (Pubitemid 44521651)
3. Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1. SV Ambudkar S Dey CA Hrycyna M Ramachandra I Pastan MM Gottesman, Annu Rev Pharmacol Toxicol 1999 39 1 361 398 10.1146/annurev.pharmtox.39.1.361 10331089 (Pubitemid 29222564)
4. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). LA Doyle DD Ross, Oncogene 2003 22 47 7340 7358 10.1038/sj.onc.1206938 14576842 (Pubitemid 37487163)
5. ABCG2: Structure, function and role in drug response. O Polgar RW Robey SE Bates, Expert Opin Drug Metabol Toxicol 2008 4 1 1 15 10.1517/17425255.4.1.1 (Pubitemid 351234097)
6. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. CGL Lee MM Gottesman CO Cardarelli M Ramachandra KT Jeang SV Ambudkar I Pastan S Dey, Biochemistry 1998 37 11 3594 3601 10.1021/bi972709x 9530286 (Pubitemid 28162914)
7. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. JD Allen SC van Dort M Buitelaar O van Tellingen AH Schinkel, Cancer Res 2003 63 6 1339 1344 12649196 (Pubitemid 36348714)
8. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. MVS Varma Y Ashokraj CS Dey R Panchagnula, Pharmacol Res 2003 48 4 347 359 10.1016/S1043-6618(03)00158-0 12902205 (Pubitemid 36945333)
9. Multidrug resistance reversal agents. J Robert C Jarry, J Med Chem 2003 46 23 4805 4817 10.1021/jm030183a 14584929 (Pubitemid 37352018)
10. Enhancement of vincristine and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its resistant sublines to vincristine and adriamycin. T Tsuruo H Iida M Yamashiro S Tsukagoshi Y Sakurai, Biochem Pharmacol 1982 31 3138 3140 10.1016/0006-2952(82)90097-1 7150340 (Pubitemid 12023072)
11. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. H Thomas HM Coley, Cancer Control 2003 10 2 159 159 12712010
12. Targeting multidrug resistance in cancer. G Szakcs JK Paterson JA Ludwig C Booth-Genthe MM Gottesman, Nat Rev Drug Discovery 2006 5 3 219 234 (Pubitemid 43336035)
13. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. C Globisch IK Pajeva M Wiese, Bioorg Med Chem 2006 14 5 1588 1598 10.1016/j.bmc.2005.10.058 16307883 (Pubitemid 43120295)
14. Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. H Müller IK Pajeva C Globisch M Wiese, Bioorg Med Chem 2008 16 5 2448 2462 18083034 (Pubitemid 351380935)
15. Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. W Klinkhammer H Müller C Globisch IK Pajeva M Wiese, Bioorg Med Chem 2009 17 6 2524 2535 10.1016/j.bmc.2009.01.072 19250834
16. S. H. R. SYBYL8.1; Tripos Inc. St. Louis, MO 63144 USA
17. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. RD Cramer DE Patterson JD Bunce, J Am Chem Soc 1988 110 18 5959 5967 10.1021/ja00226a005
18. Topomer CoMFA: a design methodology for rapid lead optimization. RD Cramer, J Med Chem 2003 46 3 374 388 10.1021/jm020194o 12540237 (Pubitemid 36139790)
19. Topomers: a validated protocol for their self-consistent generation. RJ Jilek RD Cramer, J Chem Inf Comput Sci 2004 44 4 1221 1227 15272829
20. Bioisosterism as a molecular diversity descriptor: steric fields of single "topomeric" conformers. RD Cramer RD Clark DE Patterson AM Ferguson, J Med Chem 1996 39 16 3060 3069 10.1021/jm960291f 8759627 (Pubitemid 26260311)
21. Multivariate structure-activity relationships between data from a battery of biological tests and an ensemble of chemical descriptors: The PLS method. WJ Dunn S Wold V Edlund S Hellherg J Gasteiger, Quant Struct-Act Relat 1984 3 131 137 10.1002/qsar.19840030402 (Pubitemid 15191731)
22. PLS-regression: a basic tool of chemometrics. S Wold M Sjöström L Eriksson, Chemom Intell Lab Syst 2001 58 2 109 130 10.1016/S0169-7439(01) 00155-1 (Pubitemid 33033283)
23. Partial least squares (PLS): its strengths and limitations. RD Cramer, Perspect Drug Discovery Des 1993 1 2 269 278 10.1007/BF02174528
24. HQSAR - A highly predictive QSAR technique based on molecular holograms. T Hurst T Heritage, 213th ACS Natl. Meeting San Francisco, CA, 1997, CINF 019 1997
25. SYBYL Line Notation (SLN): A Versatile Language for Chemical Structure Representation. S Ash MA Cline RW Homer T Hurst GB Smith, J Chem Inf Comput Sci 1997 37 1 71 79 (Pubitemid 127601580)
26. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. M Roe A Folkes P Ashworth J Brumwell L Chima S Hunjan I Pretswell W Dangerfield H Ryder P Charlton, Bioorg Med Chem Lett 1999 9 4 595 600 10.1016/S0960-894X(99)00030-X 10098671 (Pubitemid 29090660)